<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2020-22-25</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2838</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Роль белков, связывающих жирные кислоты, в оценке поражения почек у пациентов с анкилозирующим спондилитом</article-title><trans-title-group xml:lang="en"><trans-title>The role of fatty acid-binding proteins in evaluating kidney involvement in patients with ankylosing spondylitis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Пленкина</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Plenkina</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лидия Владимировна Пленкина;</p><p>610027, Киров, ул. К. Маркса, 112</p></bio><bio xml:lang="en"><p>Lidia Plenkina</p><p>112, K. Marx St., Kirov 610027</p></bio><email xlink:type="simple">lidia.plenkina@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Симонова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Simonova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>610027, Киров, ул. К. Маркса, 112</p></bio><bio xml:lang="en"><p>112, K. Marx St., Kirov 610027</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попова</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Popova</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>610027, Киров, ул. К. Маркса, 112</p></bio><bio xml:lang="en"><p>112, K. Marx St., Kirov 610027</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Розинова</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Rozinova</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>610027, Киров, ул. К. Маркса, 112</p></bio><bio xml:lang="en"><p>112, K. Marx St., Kirov 610027</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Кировский государственный медицинский университет» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Kirov State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>19</day><month>02</month><year>2020</year></pub-date><volume>58</volume><issue>1</issue><fpage>22</fpage><lpage>25</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Пленкина Л.В., Симонова О.В., Попова С.В., Розинова В.А., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Пленкина Л.В., Симонова О.В., Попова С.В., Розинова В.А.</copyright-holder><copyright-holder xml:lang="en">Plenkina L.V., Simonova O.V., Popova S.V., Rozinova V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2838">https://rsp.mediar-press.net/rsp/article/view/2838</self-uri><abstract><p>Поражение почек — одно из экстраартикулярных проявлений анкилозирующего спондилита (АС). В связи с рядом недостатков традиционных параметров оценки почечной функции активно ведется поиск новых маркеров.</p><p>Цель исследования — оценить мочевую экскрецию печеночной и сердечной форм белка, связывающего жирные кислоты (L-FABP и H-FABP) у пациентов с АС.</p><sec><title>Материал и методы</title><p>Материал и методы. Исследовались образцы мочи 50 пациентов (37 мужчин и 13 женщин) с достоверным диагнозом АС в возрасте не моложе 18 лет, без вторичной нефропатии (за исключением изменений, связанных с АС). Медиана возраста пациентов составила 39 [34; 56] лет, длительности АС — 10 [7; 18] лет. Уровни L-FABP и H-FABP измеряли с помощью иммуноферментного анализа. Полученные значения приводились к мочевой экскреции креатинина. Результаты сравнивались с сопоставимой по полу и возрасту группой контроля. Результаты и обсуждение. Экскреция L-FABP у пациентов с АС, не имеющих хронической болезни почек, была значимо выше, чем в контрольной группе: соответственно 0,05 [0,01; 0,09] и 0,03 [0; 0,06] нг/ммоль креатинина, (р=0,04). Экскреция H-FABP была выявлена лишь у 6 пациентов, ее уровень не превышал 601,5 нг/ммоль креатинина. У здоровых добровольцев она была меньше диапазона обнаружения. Уровень FABPs не зависел от возраста, скорости клубочковой фильтрации, активности заболевания. Содержание H-FABP коррелировало с альбуминурией (rs=0,49; p&lt;0,05). Концентрации L-FABP и H-FABP слабо коррелировали между собой (rs=0,24; p&lt;0,05).</p></sec><sec><title>Заключение</title><p>Заключение. Уровни мочевой экскреции L-FABP и H-FABP у пациентов с АС выше, чем у здоровых лиц. Выявленные корреляции могут свидетельствовать об экскреции данных видов FABPs на разных этапах почечного повреждения и, таким образом, представлять интерес для оценки уровня и стадии тубулопатии у пациентов с АС.</p></sec></abstract><trans-abstract xml:lang="en"><p>Kidney involvement is one of the extraarticular manifestations of ankylosing spondylitis (AS). Due to a number of disadvantages of traditional parameters for evaluating renal function, an active search is underway for new markers.</p><sec><title>Objective</title><p>Objective: to evaluate urinary excretion of liver-type and heart-type fatty acid-binding proteins (L-FABP and H-FABP) in patients with AS.</p></sec><sec><title>Subjects and methods</title><p>Subjects and methods. Urine samples were examined in 50 patients (37 men and 13 women) at least 18 years of age with a reliable diagnosis of AS without secondary nephropathy (with the exception of AS-associated changes). The median age of the patients was 39 [34; 56] years; the duration of AS was 10 [7; 18] years. L-FABP and H-FABP levels were measured by enzyme-linked immunosorbent assay. The values obtained were given for urinary creatinine excretion. The results were compared with those of the gender- and age-matched control group.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. L-FABP excretion in patients with AS without chronic kidney disease (CKD) was significantly higher than that in the control group: 0.05 [0.01; 0.09] and 0.03 [0; 0.06] ng/mmol of creatinine, respectively (p=0.04). Only 6 patients were found to have H-FABP excretion and its level did not exceed 601.5 ng/mmol of creatinine. In healthy volunteers, the excretion of H-FABP was below the detection range. The level of FABPs did not depend on age, glomerular filtration rate (GFR), or disease activity. The level of H-FABP correlated with albuminuria (rs=0.49; p&lt;0.05). L-FABP and H-FABP concentrations were weakly correlated with each other (rs=0.24; p&lt;0.05).</p></sec><sec><title>Conclusion</title><p>Conclusion. Urinary excretion levels of L-FABP and H-FABP are higher in patients with AS than those in healthy individuals. The found correlations may indicate the excretion of these FABPs at different stages of kidney involvement and thus be of interest for assessing the level and stage of tubulopathy in patients with AS.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>белок</kwd><kwd>связывающий жирные кислоты</kwd><kwd>L-FABP</kwd><kwd>H-FABP</kwd><kwd>анкилозирующий спондилит</kwd></kwd-group><kwd-group xml:lang="en"><kwd>fatty acid-binding protein</kwd><kwd>H-FABP</kwd><kwd>L-FABP</kwd><kwd>ankylosing spondylitis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Эрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60 doi: 10.14412/1995-4484-2015-657-660</mixed-citation><mixed-citation xml:lang="en">Erdes SĘ Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(6):657-60 (In Russ.). doi: 10.14412/1995-4484-2015-657-660</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Мазуров ВИ. Болезни суставов. Москва: СпецЛит; 2008. 397 с.</mixed-citation><mixed-citation xml:lang="en">Mazurov VI. Bolezni sustavov [Joint diseases]. Moscow: SpeczLit; 2008. 397 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Бреннер БМ. Механизмы: прогрессирования болезней почек. Нефрология. 1999;3(4):23-7 doi: 10.24884/1561-6274-1999-3-4-23-27</mixed-citation><mixed-citation xml:lang="en">Brenner BM. Mechanisms of progression of renal diseases. Nephrology. 1999;3(4):23-7 (In Russ.). doi: 10.24884/1561-6274-1999-3-4-23-27</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Fine LG, Orphanides C, Norman JT. Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int. 1998;65 Suppl:74-8.</mixed-citation><mixed-citation xml:lang="en">Fine LG, Orphanides C, Norman JT. Progressive renal disease: the chronic hypoxia hypothesis. Kidney Int. 1998;65 Suppl:74-8.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Масляков ГН, Россоловский АН, Напшева АМ. Эпителиальномезенхимальная трансформация как фактор прогрессирования хронической болезни почек. Бюллетень медицинских Интернетконференций. 2014;4(1):81-3</mixed-citation><mixed-citation xml:lang="en">Maslyakov GN, Rossolovskij AN, Napsheva AM. Epithelial-mesenchymal transformation as a factor in the progression of chronic kidney disease. Byulleten' Mediczinskikh Internet-Konferenczij. 2014;4(1):81-3 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Takaori K, Nakamura J, Yamamoto S, et al. Severity and frequency of proximal tubule injury determines renal prognosis. J Am Soc Nephrol. 2016 Aug;27(8):2393-406. doi: 10.1681/ASN.2015060647</mixed-citation><mixed-citation xml:lang="en">Takaori K, Nakamura J, Yamamoto S, et al. Severity and frequency of proximal tubule injury determines renal prognosis. J Am Soc Nephrol. 2016 Aug;27(8):2393-406. doi: 10.1681/ASN.2015060647</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Рамеев ВВ. Особенности поражения почек при АА- и AL-ами-лоидозе: Дис. ... канд. мед. наук. Москва; 2003. 131 с. [Rameev VV. Osobennostiporazheniya pochekpri AA i AL-amiloidoze</mixed-citation><mixed-citation xml:lang="en">Rameev VV. Osobennostiporazheniya pochekpri AA i AL-amiloidoze [Features of kidney damage in AA and AL amyloidosis]: Diss. ... cand. med. sci. Moscow; 2003. 131 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Yang J, Lin SC, Chen G, et al. Adiponectin promotes monocyte-to-fibroblast transition in renal fibrosis. J Am Soc Nephrol. 2013 Oct;24(10):1644-59. doi: 10.3410/f.718027784.793480779</mixed-citation><mixed-citation xml:lang="en">Yang J, Lin SC, Chen G, et al. Adiponectin promotes monocyte-to-fibroblast transition in renal fibrosis. J Am Soc Nephrol. 2013 Oct;24(10):1644-59. doi: 10.3410/f.718027784.793480779</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Шишкин АН. Анальгетическая нефропатия: скрытая угроза. Новые Санкт-Петербургские врачебные ведомости. 2003;(2):28-31</mixed-citation><mixed-citation xml:lang="en">Шишкин АН. Анальгетическая нефропатия: скрытая угроза. Новые Санкт-Петербургские врачебные ведомости. 2003;(2):28-31 [Shishkin AN. Analgesic nephropathy: a hidden threat. Novye Sankt-Peterburgskie Vrachebnye Vedomosti. 2003;(2):28-31 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Chmurzynska A. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet. 2006;47(1):39-48. doi: 10.1007/BF03194597</mixed-citation><mixed-citation xml:lang="en">Chmurzynska A. The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet. 2006;47(1):39-48. doi: 10.1007/BF03194597</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Maatman RG, van Kuppevelt TH, Veerkamp JH. Two types of fatty acidbinding protein in human kidney. Isolation, characterization and localization. Biochem J. 1991 Feb 1;273(Pt 3):759-66. doi: 10.1042/bj2730759</mixed-citation><mixed-citation xml:lang="en">Maatman RG, van Kuppevelt TH, Veerkamp JH. Two types of fatty acidbinding protein in human kidney. Isolation, characterization and localization. Biochem J. 1991 Feb 1;273(Pt 3):759-66. doi: 10.1042/bj2730759</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tsigou E, Psallida V, Demponeras C, et al. Role of new biomarkers: functional and structural damage. Crit Care Res Pract. 2013;2013:Article ID 361078, 13 p. doi: 10.1155/2013/361078</mixed-citation><mixed-citation xml:lang="en">Tsigou E, Psallida V, Demponeras C, et al. Role of new biomarkers: functional and structural damage. Crit Care Res Pract. 2013;2013:Article ID 361078, 13 p. doi: 10.1155/2013/361078</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Moore E, Bellomo R, Nichol A. Biomarkers of acute kidney injury in anesthesia, intensive care and major surgery: from the bench to clinical research to clinical practice. Minerva Anestesiol. 2010 Jun;76(6):425-40.</mixed-citation><mixed-citation xml:lang="en">Moore E, Bellomo R, Nichol A. Biomarkers of acute kidney injury in anesthesia, intensive care and major surgery: from the bench to clinical research to clinical practice. Minerva Anestesiol. 2010 Jun;76(6):425-40.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Matsui K, Kamijo-Ikemori A, Imai N, et al. Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD. Clin Exp Nephrol. 2016 Apr;20(2):195-203. doi: 10.1007/s10157-015-1144-9</mixed-citation><mixed-citation xml:lang="en">Matsui K, Kamijo-Ikemori A, Imai N, et al. Clinical significance of urinary liver-type fatty acid-binding protein as a predictor of ESRD and CVD in patients with CKD. Clin Exp Nephrol. 2016 Apr;20(2):195-203. doi: 10.1007/s10157-015-1144-9</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Nauta FL, Boertien WE, Bakker SJ, et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care. 2011 Apr;34(4):975-81. doi: 10.2337/dc10-1545</mixed-citation><mixed-citation xml:lang="en">Nauta FL, Boertien WE, Bakker SJ, et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care. 2011 Apr;34(4):975-81. doi: 10.2337/dc10-1545</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики иподходы клечению. Нефрология. 2012;16(1):89-115</mixed-citation><mixed-citation xml:lang="en">National recommendations. Chronic kidney disease: basic principles of screening, diagnosis, prevention and treatment approaches. Nefrologiya. 2012;16(1):89-115 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Xu Y, Xie Y, Shao X, et al. L-FABP: A novel biomarker of kidney disease. Clin Chim Acta. 2015 May;445:85-90. doi: 10.1016/j.cca.2015.03.017</mixed-citation><mixed-citation xml:lang="en">Xu Y, Xie Y, Shao X, et al. L-FABP: A novel biomarker of kidney disease. Clin Chim Acta. 2015 May;445:85-90. doi: 10.1016/j.cca.2015.03.017</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kamijo A, Sugaya T, Hikawa A, et al. Urinary excretion of fatty acidbinding protein reflects stress overload on the proximal tubules. Am J Pathol. 2004;165:1243-55. doi: 10.1016/S0002-9440(10)63384-6</mixed-citation><mixed-citation xml:lang="en">Kamijo A, Sugaya T, Hikawa A, et al. Urinary excretion of fatty acidbinding protein reflects stress overload on the proximal tubules. Am J Pathol. 2004;165:1243-55. doi: 10.1016/S0002-9440(10)63384-6</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Kamijo A, Sugaya T, Hikawa A, et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med. 2005;145:125-33. doi: 10.1016/j.lab.2004.12.003</mixed-citation><mixed-citation xml:lang="en">Kamijo A, Sugaya T, Hikawa A, et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med. 2005;145:125-33. doi: 10.1016/j.lab.2004.12.003</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Kamijo-Ikemori A, Sugaya T, Kimura K. Urinary fatty acid binding protein in renal disease. Clin Chim Acta. 2006;374:1-7. doi: 10.1016/j.cca.2006.05.038</mixed-citation><mixed-citation xml:lang="en">Kamijo-Ikemori A, Sugaya T, Kimura K. Urinary fatty acid binding protein in renal disease. Clin Chim Acta. 2006;374:1-7. doi: 10.1016/j.cca.2006.05.038</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
